RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Summary by AI BETAClose X

Recordati reported strong preliminary full-year 2025 results, with consolidated net revenue reaching €2,618.4 million, an 11.8% increase, driven by robust performance in both Rare Diseases and Specialty & Primary Care segments. EBITDA rose by 14.5% to €991.1 million, achieving a margin of 37.8%, while adjusted net income also grew by 14.5% to €651.1 million, representing a 24.9% margin. Net income increased by 6.5% to €443.6 million, and free cash flow was €558.8 million. Net debt stood at €2,037.3 million, below 2.1x EBITDA. For 2026, the company forecasts net revenue between €2,730-€2,800 million, EBITDA of €995-€1,030 million, and adjusted net income of €655-€685 million.

Disclaimer*

UK 100

Latest directors dealings